Powder: -20°C for 3 years | In solvent: -80°C for 1 year
THZ531 是一种选择性CDK12和CDK13共价抑制剂,IC50值分别为 158 nM 和 69 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 413 | 现货 | ||
2 mg | ¥ 556 | 现货 | ||
5 mg | ¥ 828 | 现货 | ||
10 mg | ¥ 1,330 | 现货 | ||
25 mg | ¥ 2,890 | 现货 | ||
50 mg | ¥ 4,180 | 现货 | ||
100 mg | ¥ 5,820 | 现货 | ||
500 mg | ¥ 11,600 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,070 | 现货 |
产品描述 | THZ531 is a covalent inhibitor of both CDK12(IC50=158 nM) and CDK13(IC50=69 nM). |
靶点活性 | CDK12:158 nM, CDK13:69 nM |
体外活性 | In Jurkat cell, THZ531(IC50=50 nM) treatment leads to a dramatic and irreversible decrease proliferation.THZ531 potently inhibits CDK12(IC50=158 nM) and CDK13 (IC50=69 nM). |
激酶实验 | Cells are treated with THZ531 for 6 hours.After treatment cells are washed 2-fold with cold PBS and then lysed in the following lysis buffer: Hepes(50 mM, pH 7.4), NaCl(150 mM), 1% Nonidet P40 substitute, EDTA(5 mM), DTT(1 mM), and protease/phosphatase cocktails.Lysates are treated with bio-THZ1 or bio-TH531 for pulldown overnight at 4°C. |
细胞实验 | Jurkat cells are plated in 96-well plates at 20,000 cells/well in fresh media and treated with THZ531 or DMSO at the indicated concentrations for 72 hours. HAP1 cells are seeded in 96-well plates at 12,000 cells/well in fresh media and 24 hours later are treated with THZ531 at the indicated concentrations for 72 hours. Anti-proliferative effect of THZ531 is assessed. To assess the effect of inhibitor washout on anti-proliferation of Jurkat cells, cells are treated with THZ531 or DMSO for 6 hrs. Inhibitor-containing medium is then removed and incubated with or without THZ531 for 66 hrs. Anti-proliferative effect of THZ531 is assessed. All proliferation assays are performed in biological triplicate. IC50s are determined using non-linear regression curve fit. |
分子量 | 558.07 |
分子式 | C30H32ClN7O2 |
CAS No. | 1702809-17-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 45 mg/mL (80.63 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.7919 mL | 8.9594 mL | 17.9189 mL | 44.7972 mL |
5 mM | 0.3584 mL | 1.7919 mL | 3.5838 mL | 8.9594 mL | |
10 mM | 0.1792 mL | 0.8959 mL | 1.7919 mL | 4.4797 mL | |
20 mM | 0.0896 mL | 0.448 mL | 0.8959 mL | 2.2399 mL | |
50 mM | 0.0358 mL | 0.1792 mL | 0.3584 mL | 0.8959 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
THZ531 1702809-17-3 Cell Cycle/Checkpoint CDK inhibit Cyclin dependent kinase THZ 531 THZ-531 Inhibitor inhibitor